Equillium, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Equillium, Inc. (Nasdaq: EQ) is a clinical-stage biotechnology company that develops novel immunomodulatory therapies for severe autoimmune and inflammatory disorders. Founded in 2017 and headquartered in La Jolla, California, the company focuses on precision immunotherapeutics targeting key immune pathways, including the CD6-ALCAM signaling axis and cytokine inhibition; its lead product candidate, itolizumab (EQ001), is a first-in-class anti-CD6 monoclonal antibody in Phase 3 trials for first-line acute graft-versus-host disease (aGVHD), with completed Phase 1b studies in systemic lupus erythematosus and lupus nephritis, and Phase 2 data in ulcerative colitis reported in early 2025. The pipeline also includes EQ101, a tri-specific inhibitor of IL-2, IL-9, and IL-15 for alopecia areata in Phase 1b development; EQ102, a bi-specific inhibitor of IL-15 and IL-21 for celiac disease in Phase 1; and EQ504, a selective aryl hydrocarbon receptor (AhR) modulator advancing toward a planned Phase 1 proof-of-mechanism trial by mid-2026. Recent developments encompass positive topline results from the Phase 1b EQUATE trial for itolizumab in high-risk aGVHD in 2024; a collaboration with Ono Pharmaceutical in 2023 for itolizumab commercialization in Japan, yielding a $25 million upfront payment; an August 2025 private placement financing of up to $50 million led by ADAR1 Capital Management and Janus Henderson Investors to fund EQ504 development and extend cash runway into 2027; and prior acquisitions including Bioniz Therapeutics in 2021 for cytokine inhibitors and Metacrine in 2022 adding cash reserves. Equillium operates primarily in the United States with global licensing partnerships and targets patient populations with high unmet needs in immuno-inflammatory diseases across North America, Europe, and Asia.
Company News
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
Equillium Announces Poster Presentations at the 7th International AHR Conference
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Equillium to Participate in Stifel's 2026 Virtual Immunology and Inflammation Forum
EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon
Equillium to Participate in Upcoming Investor Conferences
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Equillium, Inc. (NASDAQ:EQ) Given Consensus Recommendation of “Moderate Buy” by Analysts
EQ Works Expands Multi-Year Partnership with Leading Canadian Publisher to Include SaaS License for ClearLake
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Equiniti (EQ) Launches DealTrax™: A Digital-First Platform for Corporate Actions and M&A Events
Equillium to Participate in Oppenheimer's 2026 Innovation on the Island Event